iBio appoints David Arkowitz and António Parada as independent directors

iBio, Inc.

David Arkowitz (Alkeus Pharma CFO) and António Parada (FairJourney Biologics CEO) join board effective Nov 25, 2024.
Arkowitz brings financial expertise; Parada adds antibody discovery depth; CEO cites alignment with next-gen strategy.
Departing director General Tom Hill thanked for 16 years of service; board now three Class I directors.
Annual meeting on Nov 21 passed all proposals: elected three directors, ratified Grassi & Co., and approved say-on-pay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.